

WHAT IS CLAIMED IS:

1. Use of an adeno-associated virus (AAV) vector comprising a nucleic acid molecule encoding an Anc80 capsid protein having an amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2 and one or more transgenes selected from the group consisting of TMC1, TMC2, MYO7A, USCH1C, CDH23, PCDH15, SANS, CIB2, USH2A, VLGR1, WHRN, CLRN1, and PDZD7 in the manufacture of a pharmaceutical composition for the treatment of a hearing disorder, or for the prevention of hearing loss, wherein the one or more transgenes are delivered to an inner ear of a subject.

2. Use of an adeno-associated virus (AAV) vector comprising a nucleic acid molecule encoding an Anc80 capsid protein having an amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2 and a transgene in the manufacture of a pharmaceutical composition for the treatment of a hearing disorder, or for the prevention of hearing loss, wherein the AAV is to be administered to an inner ear of a subject, thereby delivering the transgene to one or more cells in the inner ear of the subject.

3. The use of claim 1 or 2, wherein the transgene is delivered to at least 80% of inner hair cells (IHCs) of the inner ear and to at least 80% of outer hair cells (OHCs) of the inner ear.

4. The use of claim 2, wherein the transgene is selected from the group consisting of ACTG1, ADCY1, ATOH1, ATP6V1B1, BDNF, BDP1, BSND, DATSPER2, CABP2, CD164, CDC14A, CDH23, CEACAM16, CHD7, CCDC50, CIB2, CLDN14, CLIC5, CLPP, CLRN1, COCH, COL2A1, COL4A3, COL4A4, COL4A5, COL9A1, COL9A2, COL11A1, COL11A2, CRYM, DCDC2, DFNA5, DFNB31, DFNB59, DIAPH1, EDN3, EDNRB, ELMOD3, EMOD3, EPS8, EPS8L2, ESPN, ESRRB, EYA1, EYA4, FAM65B, FOXI1, GIPC3, GJB2, GJB3, GJB6, GPR98, GRHL2, GPSM2, GRXCR1, GRXCR2, HARS2, HGF, HOMER2, HSD17B4, ILDR1, KARS, KCNE1, KCNJ10, KCNQ1, KCNQ4, KITLG, LARS2, LHFPL5, LOXHD1, LRTOMT, MARVELD2, MCM2, MET, MIR183, MIRN96, MITF, MSRB3, MT-RNR1, MT-TS1, MYH14, MYH9, MYO15A, MYO1A, MYO3A, MYO6, MYO7A, NARS2, NDP, NF2, NT3, OSBPL2, OTOA, OTOF, OTOG, OTOGL, P2RX2, PAX3, PCDH15,

PDZD7, PJVK, PNPT1, POLR1D, POLR1C, POU3F4, POU4F3, PRPS1, PTPRQ, RDX, S1PR2, SANS, SEMA3E, SERPINB6, SLC17A8, SLC22A4, SLC26A4, SLC26A5, SIX1, SIX5, SMAC/DIABLO, SNAI2, SOX10, STRC, SYNE4, TBC1D24, TCOF1, TECTA, TIMM8A, TJP2, TNC, TMC1, TMC2, TMIE, TMEM132E, TMPRSS3, TRPN, TRIOBP, TSPEAR, USH1C, USH1G, USH2A, USH2D, VLGR1, WFS1, WHRN, and XIAP.

5. The use of claim 1 or 2, wherein the transgene is a TMC1 or TMC2 transgene.

6. The use of claim 1 or 2, wherein the transgene is an Usher transgene.

7. The use of claim 6, wherein the Usher transgene is selected from the group consisting of MYO7A, USCH1C, CDH23, PCDH15, SANS, CIB2, USH2A, VLGR1, WHRN, CLRN1, PDZD7.

8. The use of any one of claims 1 to 7, wherein the transgene is further delivered to one or more cells in the inner ear selected from the group consisting of spiral ganglion neurons, vestibular hair cells, vestibular ganglion neurons, supporting cells, and cells in the stria vascularis.

9. The use of any one of claims 1 to 7, wherein the Anc80 capsid protein has the sequence shown in SEQ ID NO:1.

10. The use of any one of claims 1 to 7, wherein the Anc80 capsid protein has the sequence shown in SEQ ID NO:2.

11. The use of any one of claims 1 to 7, wherein the transgene is under control of a heterologous promoter sequence.

12. The use of claim 11, wherein the heterologous promoter sequence is selected from the group consisting of a CMV promoter, a CBA promoter, a CASI promoter, a PGK promoter, a EF-1 promoter, an alpha9 nicotinic receptor promoter, a

prestin promoter, a KCNQ4 promoter, a Myo7a promoter, a Myo6 promoter, a Gfi1 promoter, a Vglut3 promoter, and an Atoh1 promoter.

13. The use of claim 2, wherein the transgene encodes a neurotrophic factor.

5

14. The use of claim 13, wherein the neurotrophic factor is selected from the group consisting of GDNF, BDNF, NT3, and HSP70.

10

15. The use of claim 2, wherein the transgene encodes an antibody or fragment thereof.

16. The use of claim 2, wherein the transgene encodes an immunomodulatory protein.

15

17. The use of claim 2, wherein the transgene encodes an anti-oncogenic transcript.

18. The use of claim 2, wherein the transgene encodes an antisense, silencing, or long non-coding RNA species.

20

19. The use of claim 2, wherein the transgene encodes a genome editing system selected from the group consisting of a genetically-engineered zinc finger nuclease, TALEN, and CRISPR.

25

20. The use of any one of claims 1 to 7, wherein the AAV vector is to be administered via injection through the round window.

21. The use of any one of claims 1 to 7, wherein the AAV vector is to be administered during a cochleostomy or during a canalostomy.

30

22. The use of any one of claims 1 to 7, wherein the AAV vector is to be administered to the middle ear and/or the round window via one or more drug delivery vehicles.

23. The use of any one of claims 1 to 7, wherein expression of the transgene results in regeneration of inner hair cells (IHCs), outer hair cells (OHCs), spiral ganglion neurons, stria vascularis, vestibular hair cells, and/or vestibular ganglion neurons, thereby restoring hearing or vestibular function.

24. An article of manufacture comprising an adeno-associated virus (AAV) vector and a pharmaceutical composition, wherein the AAV vector comprises an Anc80 capsid protein having an amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2 and a transgene operably linked to a promoter, for use in a method of delivering the transgene to at least 80% of inner hair cells (IHCs) and to at least 80% of outer hair cells (OHCs) in a subject's inner ear to treat a hearing disorder, wherein the transgene is selected from the group consisting of ACTG1, ADCY1, ATOH1, ATP6V1B1, BDNF, BDP1, BSND, DATSPER2, CABP2, CD164, CDC14A, CDH23, CEACAM16, CHD7, CCDC50, CIB2, CLDN14, CLIC5, CLPP, CLRN1, COCH, COL2A1, COL4A3, COL4A4, COL4A5, COL9A1, COL9A2, COL11A1, COL11A2, CRYM, DCDC2, DFNA5, DFNB31, DFNB59, DIAPH1, EDN3, EDNRB, ELMOD3, EMOD3, EPS8, EPS8L2, ESPN, ESRRB, EYA1, EYA4, FAM65B, FOXI1, GIPC3, GJB2, GJB3, GJB6, GPR98, GRHL2, GPSM2, GRXCR1, GRXCR2, HARS2, HGF, HOMER2, HSD17B4, ILDR1, KARS, KCNE1, KCNJ10, KCNQ1, KCNQ4, KITLG, LARS2, LHFPL5, LOXHD1, LRTOMT, MARVELD2, MCM2, MET, MIR183, MIRN96, MITF, MSRB3, MT-RNR1, MT-TS1, MYH14, MYH9, MYO15A, MYO1A, MYO3A, MYO6, MYO7A, NARS2, NDP, NF2, NT3, OSBPL2, OTOA, OTOF, OTOG, OTOGL, P2RX2, PAX3, PCDH15, PDZD7, PJVK, PNPT1, POLR1D, POLR1C, POU3F4, POU4F3, PRPS1, PTPRQ, RDX, S1PR2, SANS, SEMA3E, SERPINB6, SLC17A8, SLC22A4, SLC26A4, SLC26A5, SIX1, SIX5, SMAC/DIABLO, SNAI2, SOX10, STRC, SYNE4, TBC1D24, TCOF1,TECTA, TIMM8A, TJP2, TNC, TMC1, TMC2, TMIE, TMEM132E, TMPRSS3, TRPN, TRIOBP, TSPEAR, USH1C, USH1G, USH2A, USH2D, VLGR1, WFS1, WHRN, and XIAP.

25. The use of claim 1, wherein the one or more transgenes are delivered to at least 80% of inner hair cells (IHCs) of the inner ear.

26. The use of claim 1, wherein the one or more transgenes are delivered to at least 90% of inner hair cells (IHCs) of the inner ear.

27. The use of claim 1, wherein the one or more transgenes are delivered to at
5 least 95% of inner hair cells (IHCs) of the inner ear.